Navigation Links
Actos Bladder Cancer Lawsuits: Next Status Conference in Federal Actos Litigation Scheduled for January 24, 2013, Bernstein Liebhard LLP Reports
Date:1/20/2013

New York, New York (PRWEB) January 20, 2013

Actos bladder cancer lawsuits continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana, Bernstein Liebhard LLP reports. The next Status Conference in the Actos litigation has been scheduled for Thursday, January 24, 2013 at 10:30 a.m. According to an agenda posted on the Court’s website on January 16th, items to be discussed include the status of federal and state filings, as well as the status of discovery. (In re: Actos Product Liability Litigation, MDL No. 2299).

“We are pleased to see this litigation moving forward, as we continue to hear from Actos users who have been diagnosed with bladder cancer,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The firm is currently offering free lawsuit evaluations to individuals who may have developed bladder cancer due to long-term use of Actos.

Actos Lawsuits
The U.S. Food & Drug Administration (FDA) ordered Takeda to add new warnings to the Actos label in June 2011, after a study found that long-term use of the drug increased the risk for bladder cancer. * While Actos is still available in the U.S., the drug has been pulled from the market in Germany and France due to its association with bladder cancer.**

Actos lawsuits pending in the Western District of Louisiana allege that Takeda Pharmaceuticals and other Defendants concealed their knowledge that Actos could increase the risk for bladder cancer, and failed to provide adequate warnings to consumers and the health care community. According to court documents, the first trial in the federal Actos litigation is scheduled to begin on November 2014, followed by the second trial in July 2015.

Since June 2011, a number of additional studies have confirmed the association between long-term use of Actos and bladder cancer. In May 2012, research published in the British Medical Journal concluded that taking Actos for two years can double the risk of developing bladder cancer. *** A second study published in the Canadian Medical Association Journal in July 2012 concluded that patients taking Actos face a 22 percent increased risk of developing bladder cancer. ****

Actos users who developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn more about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website, http://www.consumerinjurylawyers.com/. For additional information, contact a lawyer at Bernstein Liebhard LLP today at (877) 779-1414.

*fda.gov/drugs/drugsafety/ucm259150.htm
**medpagetoday.com/Endocrinology/Diabetes/26987
***bmj.com/content/344/bmj.e3645
****health.usnews.com/health-news/news/articles/2012/07/03/another-study-links-diabetes-drug-actos-to-bladder-cancer

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

###
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com

Read the full story at http://www.prweb.com/releases/actos-lawsuits/actos-bladder-cancer/prweb10340351.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. US Drug Watchdog Now Urges Families Mourning The Loss Of A Diabetic User Of The Diabetes Drug Called Actos Who Developed Bladder Cancer To Call The Johnson Law Group
2. US Drug Watchdog Now Urges Loved Ones Of Diabetics Diagnosed with Bladder Cancer To Call The Johnson Law Group If The Loved One Also Used the Diabetes Drug Called Actos
3. US Drug Watchdog Now Urges Families Of Diabetics Diagnosed with Bladder Cancer To Call The Johnson Law Group If They Used the Diabetes Drug Called Actos
4. US Drug Watchdog Now Urges Family Members Mourning The Loss Of A Loved One Who Developed Bladder Cancer After Using The Diabetes Drug Actos To Call The Johnson Law Group
5. US Drug Watchdog Now Urges Any Diabetic Who Used the Diabetes Drug Actos and Now Have Been Diagnosed with Bladder Cancer to Call The Johnson Law Group-ASAP
6. US Drug Watchdog Now Expands Their Efforts to Educate Diabetics About the Diabetes Drug Actos and Bladder Cancer, with the Suggestion Victims Call the Johnson Law Group
7. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
8. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
9. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
10. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
11. New Lawsuit alleges Actos caused Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces its ... The PluriQ™ G9™ Gene Editing System is a complete system for ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
Breaking Medicine Technology: